These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15616298)

  • 1. Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus.
    Campion JJ; McNamara PJ; Evans ME
    Antimicrob Agents Chemother; 2005 Jan; 49(1):209-19. PubMed ID: 15616298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus.
    Chung P; McNamara PJ; Campion JJ; Evans ME
    Antimicrob Agents Chemother; 2006 Sep; 50(9):2957-65. PubMed ID: 16940088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus.
    Campion JJ; Chung P; McNamara PJ; Titlow WB; Evans ME
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2189-99. PubMed ID: 15917512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.
    Campion JJ; McNamara PJ; Evans ME
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4733-44. PubMed ID: 15561851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window.
    Firsov AA; Lubenko IY; Smirnova MV; Strukova EN; Zinner SH
    Antimicrob Agents Chemother; 2008 Jun; 52(6):1924-8. PubMed ID: 18378704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model.
    Allen GP; Kaatz GW; Rybak MJ
    Int J Antimicrob Agents; 2004 Aug; 24(2):150-60. PubMed ID: 15288314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration.
    Olofsson SK; Marcusson LL; Komp Lindgren P; Hughes D; Cars O
    J Antimicrob Chemother; 2006 Jun; 57(6):1116-21. PubMed ID: 16624874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion.
    Firsov AA; Smirnova MV; Strukova EN; Vostrov SN; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2008 Dec; 32(6):488-93. PubMed ID: 18790614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance.
    Ba BB; Arpin C; Vidaillac C; Chausse A; Saux MC; Quentin C
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1931-6. PubMed ID: 16723548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].
    Cui JC; Liu YN; Wang R; Liang BB; Pei F; Zheng ZJ
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1863-6. PubMed ID: 15631794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model.
    Firsov AA; Vostrov SN; Lubenko IY; Arzamastsev AP; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2004 Jul; 54(1):178-86. PubMed ID: 15190041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
    Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
    J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli.
    Khan DD; Lagerbäck P; Malmberg C; Kristoffersson AN; Wistrand-Yuen E; Sha C; Cars O; Andersson DI; Hughes D; Nielsen EI; Friberg LE
    Int J Antimicrob Agents; 2018 Mar; 51(3):399-406. PubMed ID: 29127049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration.
    Strukova EN; Portnoy YA; Zinner SH; Firsov AA
    J Antimicrob Chemother; 2016 Mar; 71(3):678-84. PubMed ID: 26626718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Coyle EA; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1654-9. PubMed ID: 11353608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of GrlA mutation on the development of quinolone resistance in Staphylococcus aureus in an in vitro pharmacokinetic model.
    Oonishi Y; Mitsuyama J; Yamaguchi K
    J Antimicrob Chemother; 2007 Nov; 60(5):1030-7. PubMed ID: 17827137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance.
    Gumbo T; Louie A; Deziel MR; Drusano GL
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3178-81. PubMed ID: 16048921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model.
    Firsov AA; Vostrov SN; Shevchenko AA; Cornaglia G
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1281-7. PubMed ID: 9174184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
    Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.